Harrow (HROW) Stock Price
Harrow Price
Over the last 13 years Harrow grew revenue by 83.8% annually, reaching 272.30 M USD. For Harrow, the net margin of -1.9% is up versus -24.8% a few years ago. The consensus 12-month price target for Harrow is 70.00 USD, about 150.0% above where the stock trades today. Of 15 analysts, 14 rate the stock a buy — an overall Buy consensus.
Harrow stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Harrow business model & stock analysis
Frequently asked questions about Harrow
Harrow Health Inc is a pharmaceutical company that operates on a unique business model. They specialize in acquiring and commercializing branded prescription drugs. By acquiring smaller pharmaceutical companies and their products, Harrow Health Inc focuses on improving patient access to vital medications. Their business strategy involves developing partnerships, managing intellectual property, and conducting research to ensure the availability of necessary medications. Through this model, Harrow Health Inc aims to address unmet medical needs and offer innovative solutions to patients. This approach enables the company to play a significant role in the pharmaceutical industry and deliver impactful healthcare products.
Harrow Health Inc is primarily active in the healthcare industry.
The main competitors of Harrow Health Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Novartis AG.
Harrow Health Inc, formerly known as Imprimis Pharmaceuticals, is a pharmaceutical company specializing in the development and commercialization of innovative therapeutic products. Founded in 2006, the company initially focused on providing compounded medications to patients and physicians. Over the years, Harrow Health Inc expanded its portfolio, acquiring multiple ophthalmology-focused businesses and broadening its reach within the eye care industry. Today, the company's offerings include both FDA-approved and compounded medications, along with proprietary formulations and drug delivery technologies. Harrow Health Inc continues to demonstrate its commitment to improving patient access to high-quality, affordable healthcare solutions within the pharmaceutical sector.
Harrow Health Inc has accomplished several significant milestones in its history. Firstly, the company successfully expanded its pharmaceutical portfolio by acquiring Imprimis Pharmaceuticals, which greatly enhanced its product offering and market presence. Additionally, Harrow Health Inc implemented strategic partnerships and collaborations to further its growth and innovation. The company also achieved financial milestones by consistently delivering positive financial results and increasing its revenue over time. Furthermore, Harrow Health Inc demonstrated its commitment to advancing patient care by successfully launching innovative drugs and expanding its prescription services. These achievements highlight Harrow Health Inc's continuous progress, strong market position, and dedication to improving healthcare outcomes.
Harrow Health Inc is primarily present in the United States.
Harrow Health Inc represents values of innovation, patient care, and ethical practices. The company strives to develop and deliver high-quality medications and healthcare solutions that improve patient outcomes and advance medical treatments. Harrow Health Inc is committed to providing accessible and affordable pharmaceuticals while maintaining strict regulatory compliance. With a focus on research and development, the company aims to address unmet medical needs and introduce pioneering therapies to enhance overall patient well-being. Harrow Health Inc's corporate philosophy revolves around integrity, transparency, and putting patients first, driving its mission to make a significant impact in the healthcare industry.
Analysts currently set an average price target of 73.67 USD for the Harrow stock (median: 70.00 USD), implying +163.1 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Harrow stock: 14 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Harrow to generate revenue of 350.28 M USD and earnings per share of -0.07 USD.
Converted at the current exchange rate, the Harrow share trades at 24.99 EUR (28.00 USD).
The Harrow share (HROW) is listed on 1 stock exchanges, including: NASDAQ (HROW).
Harrow Health Inc is a company that specializes in the development, marketing, and sale of high-quality pharmaceuticals and medical devices. Its business model is focused on the field of ophthalmology medicine, which is a specialized niche with a high demand for innovative products and services. The company offers its products and services in various areas, including the development of eye drops and steroids. It works closely with doctors and other medical professionals to understand the needs of patients in this area and develop innovative solutions that deliver better results for patients. Another important area in which the company operates is the production of eye implants and lenses suitable for patients with a variety of eye conditions. The different types of lenses range from intraocular lenses for vision correction to multifocal lenses for older patients. Harrow Health is also active in the production of medical devices and offers a wide range of products that can be used for eye treatment. The company manufactures medical instruments for use in surgeries, diagnostic instruments for early detection of eye diseases, and even devices for data processing and analysis. One of Harrow Health's standout products is the Buccolam medication, which was developed for the treatment of epilepsy in children and adults. Buccolam is a fast-acting seizure medication offered in a rapidly dispersible formulation and is an incredibly effective treatment for seizures. Overall, the company relies on a diversified business model to ensure that it can respond to market needs while also building a stable and sustainable business. By focusing on multiple areas of ophthalmology medicine and offering a wide range of products and services, Harrow Health ensures that it can serve a variety of customers and operate very successfully in the market. In summary, Harrow Health is a strong company that specializes in pharmaceutical and medical technology for eye care. With its wide range of products such as eye drops, implants, and medical instruments, the company ensures that it can respond to the needs of patients in this field and remain relevant to ophthalmology medicine.
The expected revenue of Harrow is 350.28 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Harrow is -2.70 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Harrow is currently -381.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harrow stock.
The price-to-sales ratio (P/S) of Harrow is currently 2.94. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harrow stock.
The Eulerpool Quality Score for Harrow is 5/10.
The ISIN of Harrow is US4158581094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Harrow is A2PBJD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Harrow is HROW. The ticker symbol is used to trade Harrow shares on the stock exchange.
Harrow stock
Harrow Peer Group
Harrow Ticker
Harrow FIGI
All fundamentals and in-depth analysis of Harrow
Our stock analysis for Harrow stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harrow. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.